A detailed history of Bessemer Group Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Bessemer Group Inc holds 499 shares of ALKS stock, worth $14,361. This represents 0.0% of its overall portfolio holdings.

Number of Shares
499
Previous 270 84.81%
Holding current value
$14,361
Previous $7,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.01 - $28.55 $5,269 - $6,537
229 Added 84.81%
499 $14,000
Q2 2024

Aug 13, 2024

BUY
$23.21 - $27.24 $464 - $544
20 Added 8.0%
270 $7,000
Q1 2024

May 13, 2024

BUY
$26.4 - $32.56 $6,600 - $8,140
250 New
250 $7,000
Q4 2022

Feb 13, 2023

BUY
$21.94 - $26.24 $3,181 - $3,804
145 New
145 $4,000
Q4 2017

Jan 30, 2018

SELL
$47.69 - $55.39 $22,366 - $25,977
-469 Closed
0 $0
Q3 2017

Nov 03, 2017

BUY
$49.16 - $54.45 $23,056 - $25,537
469
469 $24,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.73B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.